Formulation of 5-HT agonist and NSAID for treatment of migraine
August 14, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesTreatment of dysmenorrhea and migraine symptoms Heterocyclic compounds Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them 1,4 benzodioxin derivatives and their use as serotonin 5HT1A agonists Treatment of vascular headache and atypical facial pain Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog Indole derivatives as 5-HT1-like agonists for use in migraine Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines Patent #: 5618816 InventorApplicationNo. 907826 filed on 08/14/1997US Classes:514/415, The bicyclo ring system consists of the five-membered hetero ring and a benzene ring (e.g., indole, etc.)514/569, Polycyclo ring system514/570, Carboxy or salt thereof only attached indirectly to the benzene ring514/629R is hydrogen or a lower saturated alkyl of less than seven carbonsExaminersPrimary: Jarvis, William R. A.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/405A61K 031/19 A61K 031/16 AbstractThis invention comprises a method of treating migraine in a human comprising co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective amount of an analgesic, particularly a long-acting NSAID in doses below those ordinarily considered as minimum effective doses as to both 5-HT agonist and long-acting NSAID. Dosage forms are also included herein.Other References
| |
